162 results
Page 3 of 9
8-K
EX-99.1
h0anlb cb
3 Nov 21
Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business
7:10am
8-K
EX-99.1
y48izvxhlil1
5 Aug 21
Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results
7:11am
DEFA14A
qkv0p r199ta2etprp
3 May 21
Additional proxy soliciting materials
7:21am
8-K
EX-99.1
9xzaevqn
3 May 21
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
7:20am
8-K
r31t d8yc
3 May 21
Departure of Directors or Certain Officers
7:18am
8-K
EX-10.3
san9u
3 May 21
Departure of Directors or Certain Officers
7:18am
8-K
EX-10.2
rk07q9dhw2rxiwv
3 May 21
Departure of Directors or Certain Officers
7:18am
DEFA14A
5ejpknw0
7 Apr 21
Additional proxy soliciting materials
4:28pm
8-K
EX-99.1
ewyrfsd4bnh2syba
11 Feb 21
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
7jy 90irg6p9jym
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
EX-99.1
dobz iazxrv69ayu
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
rbwran c0f
17 Dec 20
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
EX-3.1
pq4qln77 n9l
17 Dec 20
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
EX-99.1
nfn otq80my2
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.2
fnol0okfufgee86f ldb
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm